INSYS Therapeutics, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2018. For the quarter, the company reported net revenue of $18,346,000 compared to $30,670,000 a year ago. Loss from operations was $30,819,000 compared to $175,743,000 a year ago. Loss before income taxes was $30,336,000 compared to $175,316,000 a year ago. Net loss was $30,576,000 or $0.41 per diluted share compared to $166,280,000 or $2.28 per diluted share a year ago. Adjusted LBITDA was $25,988,000 compared to $18,391,000 a year ago. Adjusted loss before income taxes was $27,443,000 compared to $19,698,000 a year ago. Adjusted net loss was $27,743,000 or $0.37 per diluted share compared to $15,335,000 or $0.21 per diluted share a year ago. LBITDA was $28,881,000 against $174,009,000 for the same period a year ago. For the nine months, the company reported net revenue of $65,723,000 compared to $109,208,000 a year ago. Loss from operations was $78,757,000 compared to $198,370,000 a year ago. Loss before income taxes was $77,759,000 compared to $197,004,000 a year ago. Net loss was $78,296,000 or $1.06 per diluted share compared to $180,908,000 or $2.50 per diluted share a year ago. Adjusted LBITDA was $63,353,000 compared to $24,561,000 a year ago. Adjusted loss before income taxes was $67,572,000 compared to $28,656,000 a year ago. Adjusted net loss was $66,044,000 or $0.89 per diluted share compared to $20,233,000 or $0.28 per diluted share a year ago. LBITDA was $73,540,000 against $192,909,000 for the same period a year ago.